Several other equities research analysts have also recently weighed in on EPIX. HC Wainwright restated a buy rating on shares of ESSA Pharma in a research note on Friday, May 17th. Zacks Investment Research upgraded ESSA Pharma from a sell rating to a buy rating and set a $2.50 target price for the company in a research note on Wednesday, May 22nd.
EPIX stock traded down $0.14 during trading on Thursday, hitting $1.75. 385 shares of the company’s stock were exchanged, compared to its average volume of 17,336. The firm’s 50-day moving average price is $2.45. The firm has a market capitalization of $15.05 million, a PE ratio of -0.69 and a beta of 1.93. ESSA Pharma has a 52-week low of $1.56 and a 52-week high of $4.50. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.44 and a quick ratio of 2.44.
ESSA Pharma Company Profile
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
See Also: Economic Reports
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.